

October 1, 2020

Dear Colleague:

NCQA is pleased to present the HEDIS^{®1} *Measurement Year (MY) 2020 Volume 2: Technical Update*. With this release, NCQA freezes the Volume 2 technical specifications for MY 2020, with the exception of measures that require pharmacy data and the Risk Adjusted Utilization measures. This memo contains corrections, policy changes and clarifications to HEDIS MY 2020 & MY 2021 Volume 2. Review all items in the table below and incorporate them into your implementation processes.

Changes in this memo also apply to MY 2021, but the technical specifications for MY 2021 will not be frozen until the release of the *HEDIS MY 2021 Volume 2: Technical Update* on March 31, 2021. Changes in that update will only apply to MY 2021.

Measures that require pharmacy data and the Risk Adjusted Utilization measures will be final when the Medication List Directory (MLD) and the risk-adjustment tables are posted on November 2, 2020.

Obtaining the MLD. Changes to medications and an update memo (if needed) are included in the MLD, which will be available for download on November 2. Order it for free from the NCQA Store at <https://store.ncqa.org/index.php/catalog/product/view/id/3763/s/hedis-my-2020-medication-list-directory/>.

Obtaining the updated Value Set Directory (VSD). Go to “My Downloads” at <https://my.ncqa.org/Downloads> and download the VSD again to obtain the October 1 version, which contains all coding changes. The NCQA Download Center does not list the VSD as “October 1 version” in the Item Name column, but the updated version date will display in the filename once the file has been downloaded. Refer to the Summary of Changes spreadsheets in the VSD to identify codes and value sets that were added, deleted or revised.

If information in this memo contradicts a previous Policy Clarification Support (PCS) system response, then the PCS response is obsolete. The changes in this document are required for HEDIS MY 2020 & MY 2021 reporting.

If you have questions about information included in the *Technical Update* or about other measure specifications, contact us through My NCQA (<https://my.ncqa.org>). We wish everyone a successful HEDIS data collection season!

Sincerely,

Cindy Ottone, MHA
Director, Policy-Measures

Enclosure

¹HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).

NCQA Copyright Notice and Disclaimer

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. **Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program.** Reprinted with permission by NCQA. © 2020 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measure specifications.

The American Hospital Association holds a copyright to the Uniform Billing Codes ("UB") contained in the measure specifications. Any use of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.

Some measure specifications contain coding from LOINC® (<http://loinc.org>). The LOINC table, LOINC codes, LOINC panels and form file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright © 1995–2020 Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and are available at no cost under the license at <http://loinc.org/terms-of-use>.

"SNOMED" and "SNOMED CT" are registered trademarks of the International Health Terminology Standards Development Organisation (IHTSDO).

"HL7" is the registered trademark of Health Level Seven International.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without the written permission of NCQA.

NCQA Measure Adjustment and Certification Notices

Unadjusted Certified Measures: A calculated measure result (a "rate") from a HEDIS measure that has been certified via NCQA's Measure Certification Program, and is based on unadjusted HEDIS specifications, may not be called a "Health Plan HEDIS rate" until it is audited and designated reportable by an NCQA-Certified HEDIS Compliance Auditor. Until such time, applicable measure rates shall be designated or referred to as "Unaudited Health Plan HEDIS Rates."

Adjusted Certified Measures: A calculated measure result (a "rate") from a HEDIS measure that has been certified via NCQA's Measure Certification Program, and is based on adjusted HEDIS specifications, may not be called an "Adjusted HEDIS rate" until it is audited and designated reportable by an NCQA-Certified HEDIS Compliance Auditor. Until such time, applicable measure rates shall be designated or referred to as "Adjusted, Unaudited HEDIS Rates."

Unadjusted Uncertified Measures: A calculated measure result (a "rate") from a HEDIS measure that has not been certified via NCQA's Measure Certification Program, and is based on unadjusted HEDIS specifications, may not be called a "Health Plan HEDIS rate" until it is audited and designated reportable by an NCQA-Certified HEDIS Compliance Auditor. Until such time, such measure rates shall be designated or referred to as "Uncertified, Unaudited Health Plan HEDIS Rates" and may only be used for population health purposes within an affiliated health plan network and internal, quality improvement purposes (e.g., trend analysis).

Adjusted Uncertified Measures: A calculated measure result (a "rate") from a HEDIS measure that has not been certified via NCQA's Measure Certification Program, and is based on adjusted HEDIS specifications, may not be called an "Adjusted HEDIS rate" until it is audited and designated reportable by an NCQA-Certified HEDIS Compliance Auditor. Until such time, such measure rates shall be designated or referred to as "Adjusted, Uncertified, Unaudited HEDIS Rates" and may only be used for population health purposes within an affiliated health plan network and internal, quality improvement purposes (e.g., trend analysis).

Uncertifiable Measures: Certain measures are not eligible for certification under NCQA's Measure Certification Program. As such, they should be designated or referred to as "Uncertifiable, Unaudited Health Plan HEDIS Rates" or "Adjusted, Uncertifiable, Unaudited HEDIS Rates," as applicable. A list of Uncertifiable Measures can be found on NCQA's website.

Specification Updates

This document contains corrections, policy changes and clarifications to *HEDIS MY 2020 & MY 2021 Volume 2: Technical Specifications*. NCQA has identified the appropriate page number, measure/guideline and head/subtitle for each item.

| Page | Measure/Guideline | Head/Subtitle | Update |
|------|--|---|---|
| 4 | What's New in Volume 2? | HEDIS MY 2019 first-year measure evaluation | <p>Replace the text in this section with the following text:</p> <p>The following MY 2019 <i>first-year and first-year status measures and product lines</i> will be publicly reported for MY 2020:</p> <ul style="list-style-type: none"> • Follow-Up After High-Intensity Care for Substance Use Disorder (FUI). • Pharmacotherapy for Opioid Use Disorder (POD). • Hospitalization Following Discharge from a Skilled Nursing Facility (HFS). • Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) – Medicare and commercial product lines. • Plan All-Cause Readmissions (PCR)—Medicaid product line; Medicare Skilled Nursing Care rate —65+ age range only. <p>The following MY 2018 first-year measure will be publicly reported for MY 2020. This is the first measure using the ECDS reporting method to be publicly reported.</p> <ul style="list-style-type: none"> • Prenatal Immunization Status (PRS). |
| 7 | Reporting Data Errors to NCQA | Reporting Data Errors to NCQA | <p>Add the following sentence to the end of the first paragraph:</p> <p>NCQA reserves the right to publicly display the information on the reported issue, including, but not limited to, the affected organization, the specific data error and the associated resolution. We will display the information on a dedicated public-facing webpage on the NCQA website (www.ncqa.org). NCQA may also revise affected products.</p> |
| 14 | How NCQA Defines an Organization for Accreditation | 5. HEDIS/CAHPS reporting unit | <p>Remove the following text at the end of the paragraph:</p> <p>Refer to <i>HEDIS Reporting for Accreditation</i>, below, for the definition of a reporting unit.</p> |
| 15 | How NCQA Defines an Organization for Accreditation | 7. Geographic unit | <p>Replace the last paragraph with the following text:</p> <p>For PPO products—which may have a service area larger than a single state—the organization is required to report HEDIS/CAHPS results for geographic regions no larger than a state.</p> |

| Page | Measure/Guideline | Head/Subtitle | Update |
|------|---|--|---|
| 25 | General Guideline 18 | Deceased Members | <p>Replace the first and second paragraphs with the following text:</p> <p>Members who die during the measurement year are treated as an optional exclusion. Refer to the <i>Optional Exclusions</i> guideline in the <i>Guidelines for Effectiveness of Care Measures</i>. These members may be identified using various methods that include, but are not limited to, enrollment data, medical record, claims/encounter data or supplemental data.</p> <p>Organizations should attempt to remove these members prior to drawing the sample for hybrid measures. If during medical record review a member is found to be deceased, the member can be removed as a valid data error from the sample and replaced by a member from the oversample.</p> |
| 25 | General Guideline 18 | Deceased Members—Note | <p>Replace the second bullet with the following text:</p> <ul style="list-style-type: none"> • <i>Deceased members are not excluded from measures in the Health Plan Descriptive domain or the Utilization domain (except for measures similar to Effectiveness of Care measures: Well-Child Visits in the First 30 Months of Life and Child and Adolescent Well-Care Visits).</i> |
| 35 | General Guideline 33 | Date of Service for Laboratory Tests | <p>Replace the fourth paragraph with the following two paragraphs:</p> <p>When abstracting laboratory tests from the medical record for use in hybrid reporting or for nonstandard supplemental data, the documentation must include the test date and the result (or evidence that the test was performed). The result/reported date may be used as the test date.</p> <p>Organizations may consider all events with dates no more than seven days apart to be the <i>same</i> test and may use the collected date for reporting. For example:</p> |
| 174 | Statin Therapy for Patients With Cardiovascular Disease | Data Elements for Reporting—Table SPC-1/2/3: Data Elements for Statin Therapy for Patients With Cardiovascular Disease | In the “Number of required exclusions” row, replace the language in the Administrative column with “ <i>Rate 1, for each age/gender stratification and total.</i> ” |
| 180 | Cardiac Rehabilitation | Data Elements for Reporting—Table CRE—1/2/3: Data Elements for Cardiac Rehabilitation | In the “Number of required exclusions” row, replace the language in the Administrative column with “ <i>For each age stratification and total.</i> ” |
| 196 | Comprehensive Diabetes Care | Hybrid Specification—Exclusions (optional) | <p>Replace the second sentence with the following text:</p> <p>Identify members who did not have a diagnosis of diabetes, in any setting, during the measurement year or the year prior to the measurement year and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes in any setting during the measurement year or the year prior to the measurement year.</p> |

| Page | Measure/Guideline | Head/Subtitle | Update |
|------|--|--|--|
| 206 | Kidney Health Evaluation for Patients With Diabetes | Administrative Specification—Numerator, Kidney Health Evaluation | Replace the first sentence with the following text: Members who received both an eGFR and a uACR during the measurement year on the same or different dates of service. |
| 206 | Kidney Health Evaluation for Patients With Diabetes | Administrative Specification—Numerator, Kidney Health Evaluation | Replace the second bullet with the following text: <ul style="list-style-type: none"> • At least one uACR identified by either of the following: <ul style="list-style-type: none"> – Both a quantitative urine albumin test (<u>Quantitative Urine Albumin Lab Test Value Set</u>) and a urine creatinine test (<u>Urine Creatinine Lab Test Value Set</u>) with service dates four days or less apart. For example, if the service date for the quantitative urine albumin test was December 1 of the measurement year, then the urine creatinine test must have a service date on or between November 27 and December 5 of the measurement year. – A uACR (<u>Urine Albumin Creatinine Ratio Lab Test Value Set</u>). |
| 216 | Statin Therapy for Patients With Diabetes | Data Elements for Reporting—Table SPD-1/2/3: Data Elements for Statin Therapy for Patients With Diabetes | In the “Number of required exclusions” row, replace the language in the Administrative column with “Rate 1.” |
| 290 | Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia | Eligible Population—Event/diagnosis—Step 1 | Add the following text as a new bullet and dash under the second dash: <ul style="list-style-type: none"> • At least two visits in an outpatient, intensive outpatient, partial hospitalization, ED or nonacute inpatient setting, on different dates of service, with any diagnosis of schizophrenia or schizoaffective disorder. Two of any of the following: <ul style="list-style-type: none"> – An outpatient visit with any diagnosis of schizophrenia or schizoaffective disorder (<u>Visit Setting Unspecified Value Set</u> with <u>Outpatient POS Value Set</u> with <u>Schizophrenia Value Set</u>). |
| 360 | Use of High-Risk Medications in Older Adults | Data Elements for Reporting—Table DAE-3: Data Elements for Use of High-Risk Medications in Older Adults | In the “Number of required exclusions” row, replace the language in the Administrative column with a check mark “✓.” |
| 416 | Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment | Administrative Specification—Numerator, Initiation of AOD Treatment | In the third bullet on page 416 replace “(Telephone Visit Value Set)” with “(Telephone Visits Value Set).” |

| Page | Measure/Guideline | Head/Subtitle | Update |
|------|---|--|--|
| 503 | Guidelines for Risk Adjusted Utilization Measures | Risk Adjustment Comorbidity Category Determination | <p>Add the following text as a new Note under Example: Table HCC—Comb:</p> <p>Note</p> <ul style="list-style-type: none"> For the PCR Medicaid product line only, organizations must use the “RAU Table – PCR Medicaid” risk adjustment table when assigning comorbid and discharge conditions. For all other measures and the commercial and Medicare PCR product lines, organizations must use the “RAU Shared Tables” risk adjustment table when assigning comorbid and discharge conditions. |
| 505 | Plan All-Cause Readmissions | Definitions—Plan population | <p>Replace this definition with the following text:</p> <p>Members in the eligible population prior to exclusion of outliers (denominator steps 1–5). The plan population is only used as a denominator for the Outlier Rate.</p> <p>The plan population is based on members, not discharges. Count members only once in the plan population.</p> <p>Assign members to the product/product line in which they are enrolled at the start of the continuous enrollment period of their earliest Index Hospital Stay. If the member has a gap at the beginning of this continuous enrollment period, assign the member to the product/product line in which they were enrolled as of their first enrollment segment during this continuous enrollment period.</p> |
| 505 | Plan All-Cause Readmissions | Definitions—Outlier | <p>Replace the last paragraph with the following text:</p> <p>Assign members to the product/product line in which they are enrolled at the start of the continuous enrollment period of their earliest Index Hospital Stay. If the member has a gap at the beginning of this continuous enrollment period, assign the member to the product/product line in which they were enrolled as of their first enrollment segment during this continuous enrollment period.</p> |
| 505 | Plan All-Cause Readmissions | Definitions—Nonoutlier | <p>Replace this definition with the following text:</p> <p>Members in the eligible population who are not considered outliers.</p> |
| 514 | Hospitalization Following Discharge From a Skilled Nursing Facility | Definitions—Planned Hospital Stay | <p>Replace the reference to “step 2” with “step 3.”</p> |
| 551 | Enrollment by Product Line | Calculations—Member Months | <p>Replace the second sentence with the following text:</p> <p>IDSS will convert these to member years.</p> |
| 553 | Enrollment by Product Line | Table Instructions | <p>Remove the entire “Table Instructions” section.</p> |
| 556 | Language Diversity of Membership | Calculations—Table instructions | <p>Replace both paragraphs with the following text:</p> <p>Report the number of members for whom the organization has information about spoken language preferred for health care and for written materials for each product population. If any of these data are unknown or unavailable, report as “Unknown.”</p> |

| Page | Measure/Guideline | Head/Subtitle | Update |
|-----------|---|--|--|
| 556 & 557 | Language Diversity of Membership | Calculations—Data Source, Spoken language preferred for health care, Preferred language for written materials and Other language needs | Replace all references to “percentage” with “number.” |
| 559 | Race/Ethnicity Diversity of Membership | Calculations—Table instructions | Replace both paragraphs with the following text: Report the number of members by race/ethnicity for the product population. If a member’s race or ethnicity is unknown or unavailable, report as “Unknown.” |
| 559 | Race/Ethnicity Diversity of Membership | Calculations—Data Source | Replace the first sentence in the first paragraph with the following text: Report the number of members for whom data have been collected from each data source for race and ethnicity. |
| 562 | Race/Ethnicity Diversity of Membership | Table RDM-B-1/2/3: Percentage of Members for Whom the Organization Has Race/Ethnicity Information by Data Collection Method | Add light gray shading to all cells in the “Percentage” column. |
| 562 | Race/Ethnicity Diversity of Membership | Table RDM-B-1/2/3: Percentage of Members for Whom the Organization Has Race/Ethnicity Information by Data Collection Method | Add light gray shading to the Total cells in the “Members” column. |
| 572 | Guidelines for Measures Reported Using ECDS | Guidelines—5. Member Allocation for HEDIS ECDS Reporting | Replace both bullets with the following text: <ul style="list-style-type: none"> • For commercial and Medicare, members must be continuously enrolled with no gap of more than 45 days during each year of the specified Participation Period. • For Medicaid, member enrollment is verified monthly and the member may not have a gap of more than 30 days during each year of the specified Participation Period. |
| 608 | Depression Remission or Response for Adolescents and Adults | Data Elements for Reporting—Table DRR-E-3: Data Elements for Depression Remission or Response for Adolescents and Adults (Medicare) | Remove the “12-17” age range in the “Age” column. |